Bulk Inquiry
IITZ-01
- Soluble in DMSO
- MF: C26H23FN8O
- MW: 482.51
Description
IITZ-01 is a potent lysosomotropic autophagy inhibitor which has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo. Screening against the growth of cancer cell lines MCF-7, MDAMB-231, PC-3, DU-145, HT-29 and HGC-27 gave IC50 values of 1.0 µM, 1.5 µM, 0.8 µM, 1.0 µM, 1.1 µM, 0.8 µM, respectively.
More Information
| Parent CAS No. | 1807988-47-1 |
|---|---|
| Chemical Name | N2-(4-(1H-Benzo[d]imidazol-2-yl)phenyl)-N4-(4-fluorophenyl)-6-morpholino-1,3,5-triazine-2,4-diamine |
| SMILES | C1(C2=NC3C=CC=CC=3N2)C=CC(NC2N=C(N3CCOCC3)N=C(NC3C=CC(F)=CC=3)N=2)=CC=1 |
| MFCD | N.A. |
| InChi | InChI=1S/C26H23FN8O/c27-18-7-11-20(12-8-18)29-25-32-24(33-26(34-25)35-13-15-36-16-14-35)28-19-9-5-17(6-10-19)23-30-21-3-1-2-4-22(21)31-23/h1-12H,13-16H2,(H,30,31)(H2,28,29,32,33,34) |
| InChiKey | XGEDDGLPNSLBFE-UHFFFAOYSA-N |
| CID | 134817273 |
| Short Description | Autophagy inhibitor |
References
- GJ Kumar et al. Synthesis and characterization of new s-triazine bearing benzimidazole and benzothiazole derivatives as anticancer agents. Medicinal Chemistry Research. December 2015, Volume 24, Issue 12, pp 3991–4001.
- L Guntuku et al. IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo. Oncogene. 2019 Jan;38(4):581-595.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 2425 | MHY 1485 |
From $77.00 |
| 2512 | Spautin 1 |
From $104.50 |
| 2627 | SMER 28 |
From $88.00 |
| 2679 | AR7 |
From $99.00 |
| 2894 | STF 62247 |
From $93.50 |
| 2902 | QX77 |
From $132.00 |
| 2932 | MSL-7 |
From $132.00 |
| 3429 | Indophagolin |
From $143.00 |
| 3580 | DC-LC3in-D5 |
From $154.00 |
| 3843 | LYN-1604 dihydrochloride |
From $143.00 |
| 4119 | XIE62-1004 |
From $121.00 |
